Physician profile
Vincent Chan
NPI 1770678336
$7,369.01
in general payments reported to CMS, 2019-2025
39 companies · $963 in 2025
The $963 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $752 · 2020: $655 · 2021: $978 · 2022: $1,114 · 2023: $1,497 · 2024: $1,411 · 2025: $963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,826 · Education: $45.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,825.77 |
| Education | $45.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,751.70 | 2019-2025 | Rinvoq, Skyrizi, Mavyret |
| Takeda Pharmaceuticals U.S.A., INC. | $1,015.59 | 2019-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $598.12 | 2019-2025 | Trulance, Relistor |
| Celgene Corporation | $484.47 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $367.53 | 2019-2024 | Ocaliva |
| Braintree Laboratories, INC. | $201.28 | 2019-2024 | Sutab |
| Ardelyx, INC. | $175.62 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $164.98 | 2022-2025 | |
| Daiichi Sankyo INC. | $154.58 | 2019-2023 | Injectafer |
| Janssen Biotech, INC. | $122.08 | 2021-2025 | Stelara, Simponi, Remicade |
| Phathom Pharmaceuticals, INC. | $108.87 | 2024 | Voquezna |
| Gilead Sciences, INC. | $96.14 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $96.03 | 2020-2022 | |
| Qol Medical, LLC | $91.15 | 2023 | Sucraid |
| Ferring Pharmaceuticals INC. | $90.05 | 2019-2023 | Clenpiq |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vincent Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.